Search Results

You are looking at 61 - 70 of 237 items for :

  • "neoadjuvant chemotherapy" x
Clear All
Full access

Philippe E. Spiess, Neeraj Agarwal, Rick Bangs, Stephen A. Boorjian, Mark K. Buyyounouski, Peter E. Clark, Tracy M. Downs, Jason A. Efstathiou, Thomas W. Flaig, Terence Friedlander, Richard E. Greenberg, Khurshid A. Guru, Noah Hahn, Harry W. Herr, Christopher Hoimes, Brant A. Inman, Masahito Jimbo, A. Karim Kader, Subodh M. Lele, Joshua J. Meeks, Jeff Michalski, Jeffrey S. Montgomery, Lance C. Pagliaro, Sumanta K. Pal, Anthony Patterson, Elizabeth R. Plimack, Kamal S. Pohar, Michael P. Porter, Mark A. Preston, Wade J. Sexton, Arlene O. Siefker-Radtke, Guru Sonpavde, Jonathan Tward, Geoffrey Wile, Mary A. Dwyer and Lisa A. Gurski

stage (ie, positive nodes or perivesical tissue involvement) or presence of a positive margin, similar to that for patients who undergo a radical cystectomy. Neoadjuvant Chemotherapy One of the most noteworthy issues in treatment is the optimal

Full access

Borislav Hristov, Ori Shokek and Deborah A. Frassica

-Yanguas M . A study of the response of osteogenic sarcoma and adjacent normal tissues to radiation . Int J Radiat Oncol Biol Phys 1981 ; 7 : 593 – 595 . 25. DeLaney TF Spiro IJ Suit HD . Neoadjuvant chemotherapy and radiotherapy for large

Full access

Philippe E. Spiess

distant disease) were treated with neoadjuvant chemotherapy (paclitaxel, ifosfamide, and cisplatin) and then surgical resection. They reported an objective response rate of 50%. “On the whole, this is far superior to what we see traditionally with surgery

Full access

James E. Montie, Peter E. Clark, Mario A. Eisenberger, Rizk El-Galley, Richard E. Greenberg, Harry W. Herr, Gary R. Hudes, Deborah A. Kuban, Timothy M. Kuzel, Paul H. Lange, Subodh M. Lele, Jeffrey Michalski, Anthony Patterson, Kamal S. Pohar, Jerome P. Richie, Wade J. Sexton, William U. Shipley, Eric J. Small, Donald L. Trump, Phillip J. Walther and Timothy G. Wilson

: comparison of contrast-enhanced CT, T1- and T2-weighted MR imaging, dynamic gadolinium-enchanced imaging, and late gadolinium-enhancing imaging . Radiology 1994 ; 193 : 239 – 245 . 25 Grossman HB Natale RB Tangen CM . Neoadjuvant chemotherapy

Full access

Al B. Benson III, Alan P. Venook, Tanios Bekaii-Saab, Emily Chan, Yi-Jen Chen, Harry S. Cooper, Paul F. Engstrom, Peter C. Enzinger, Moon J. Fenton, Charles S. Fuchs, Jean L. Grem, Axel Grothey, Howard S. Hochster, Steven Hunt, Ahmed Kamel, Natalie Kirilcuk, Lucille A. Leong, Edward Lin, Wells A. Messersmith, Mary F. Mulcahy, James D. Murphy, Steven Nurkin, Eric Rohren, David P. Ryan, Leonard Saltz, Sunil Sharma, David Shibata, John M. Skibber, Constantinos T. Sofocleous, Elena M. Stoffel, Eden Stotsky-Himelfarb, Christopher G. Willett, Kristina M. Gregory and Deborah Freedman-Cass

neoadjuvant chemotherapy preceding chemoRT and resection for stage II/III rectal cancer. 12 – 17 In the Spanish GCR-3 phase II trial, patients were randomized to receive CapeOx either before chemoRT or after surgery. 14 Similar pathologic complete response

Full access

Nicholas Zdenkowski, Phyllis Butow, Andrew Spillane, Charles Douglas, Kylie Snook, Mark Jones, Christopher Oldmeadow, Sheryl Fewster, Corinna Beckmore, Frances M. Boyle and for the Australia and New Zealand Breast Cancer Trials Group

Killelea BK . Use of neoadjuvant chemotherapy for patients with stage I to III breast cancer in the United States . Cancer 2015 ; 121 : 2544 – 2552 . 11. Shin HC Han W Moon HG . Breast-conserving surgery after tumor downstaging by

Full access

Wells A. Messersmith

Guidelines clearly distinguish between resectable/curative disease and unresectable disease. For patients with resectable tumors, “You can go straight to resection or consider neoadjuvant chemotherapy,” Dr. Messersmith said. For those with resectable

Full access

Peter E. Clark, Neeraj Agarwal, Matthew C. Biagioli, Mario A. Eisenberger, Richard E. Greenberg, Harry W. Herr, Brant A. Inman, Deborah A. Kuban, Timothy M. Kuzel, Subodh M. Lele, Jeff Michalski, Lance C. Pagliaro, Sumanta K. Pal, Anthony Patterson, Elizabeth R. Plimack, Kamal S. Pohar, Michael P. Porter, Jerome P. Richie, Wade J. Sexton, William U. Shipley, Eric J. Small, Philippe E. Spiess, Donald L. Trump, Geoffrey Wile, Timothy G. Wilson, Mary Dwyer and Maria Ho

involvement), similar to that for patients who undergo a radical cystectomy. Neoadjuvant Chemotherapy Increasing data support the role of neoadjuvant chemotherapy before cystectomy for T2 and T3 lesions. 40 – 42 Two randomized trials showed a survival

Full access

Thomas Schmidt, Florian Lordick, Ken Herrmann and Katja Ott

posttherapeutic FDG-negative tumor is not synonymous with a pCR. Recently, the CROSS study group showed that pCR after neoadjuvant chemotherapy increases with time from completion of chemoradiotherapy. 41 So far no data are available on posttherapeutic evaluation

Full access

Margaret A. Tempero

of neoadjuvant chemotherapy (FOLFIRINOX for 2 months) and chemoradiation followed by surgical resection and adjuvant gemcitabine. Early findings have been encouraging, Dr. Tempero indicated. A larger trial in borderline resectable disease will